Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 9/2021

22.02.2021 | Original Article – Clinical Oncology

Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients

verfasst von: Sun Min Lim, Min Hee Hong, Sang-Jun Ha, Daehee Hwang, Sehyun Chae, Yoon Woo Koh, Eun Chang Choi, Se-Heon Kim, Da-Hee Kim, Sun Och Yoon, Hye Ryun Kim

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We aimed to investigate the prognostic value of multiple immune cell markers including programmed death-ligand 1 (PD-L1) and poliovirus receptor (PVR) in head and neck squamous cell carcinoma (HNSCC) using archival tumor tissues

Methods

Patients diagnosed with HNSCC who have undergone surgical resection in 2005–2012 were included. Correlations between PVR and PD-L1 expression and patient characteristics were analyzed by analysis of variance. The Kaplan–Meier method and log-rank test were used to estimate survival. P values < 0.05 were considered statistically significant.

Results

In total, 375 primary tumor tissues were analyzed using immunohistochemistry. High PVR expression was associated with a poor prognosis in terms of overall survival (OS) and recurrence-free survival (RFS), and tumors with high PVR expression were associated with a short OS. PD-L1 tumor expression did not have a prognostic impact on survival. Univariate analysis revealed that OS and RFS were affected by age and p16 and PVR expression; multivariate analysis revealed that age and p16 and PVR expression were the most important determinants of RFS.

Conclusion

PVR overexpression is a poor prognostic factor in patients with HNSCC and co-targeting PVR and PD-L1 may be a promising therapeutic option that needs further investigation.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Balermpas P et al (2016) CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer 138:171–181. https://doi.org/10.1002/ijc.29683CrossRefPubMed Balermpas P et al (2016) CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int J Cancer 138:171–181. https://​doi.​org/​10.​1002/​ijc.​29683CrossRefPubMed
Zurück zum Zitat Delvys Rodriguez-Abreu MLJ, Maen A. Hussein, Manuel Cobo, Anjan Jayantilal Patel, Nevena Milica Secen, Ki Hyeong Lee, Bartomeu Massuti, Sandrine Hiret, James Chih-Hsin Yang, Fabrice Barlesi, Dae Ho Lee, Luis G. Paz-Ares, Robert Wenchen Hsieh, Karen Miller, Namrata Patil, Patrick Twomey, Amy V. Kapp, Raymond Meng, Byoung Chul Cho; Hospital Universitario Insular de Gran Canaria Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Abstract #9503. In: 2020 ASCO Virtual Scientific Program, 2020. J Clin Oncol Delvys Rodriguez-Abreu MLJ, Maen A. Hussein, Manuel Cobo, Anjan Jayantilal Patel, Nevena Milica Secen, Ki Hyeong Lee, Bartomeu Massuti, Sandrine Hiret, James Chih-Hsin Yang, Fabrice Barlesi, Dae Ho Lee, Luis G. Paz-Ares, Robert Wenchen Hsieh, Karen Miller, Namrata Patil, Patrick Twomey, Amy V. Kapp, Raymond Meng, Byoung Chul Cho; Hospital Universitario Insular de Gran Canaria Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). Abstract #9503. In: 2020 ASCO Virtual Scientific Program, 2020. J Clin Oncol
Zurück zum Zitat Daniel WW (1990) Spearman rank correlation coefficient. PWS-Kent, Boston Daniel WW (1990) Spearman rank correlation coefficient. PWS-Kent, Boston
Zurück zum Zitat Hunter JE, Schmidt FL (1990) Methods of meta-analysis: correcting error and bias in research findings. Sage, Newbury Park, CA Hunter JE, Schmidt FL (1990) Methods of meta-analysis: correcting error and bias in research findings. Sage, Newbury Park, CA
Zurück zum Zitat Rodriguez-Abreu D, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE) In: ASCO 2020, 2020. vol Abstract #9503. Rodriguez-Abreu D, et al. Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE) In: ASCO 2020, 2020. vol Abstract #9503.
Zurück zum Zitat Wiegand S, Zimmermann A, Wilhelm T, Werner JA (2015) Survival after distant metastasis in head and neck cancer. Anticancer Res 35:5499–5502PubMed Wiegand S, Zimmermann A, Wilhelm T, Werner JA (2015) Survival after distant metastasis in head and neck cancer. Anticancer Res 35:5499–5502PubMed
Metadaten
Titel
Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients
verfasst von
Sun Min Lim
Min Hee Hong
Sang-Jun Ha
Daehee Hwang
Sehyun Chae
Yoon Woo Koh
Eun Chang Choi
Se-Heon Kim
Da-Hee Kim
Sun Och Yoon
Hye Ryun Kim
Publikationsdatum
22.02.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 9/2021
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-021-03531-8

Weitere Artikel der Ausgabe 9/2021

Journal of Cancer Research and Clinical Oncology 9/2021 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.